RA Cap­i­tal aims to take pre­clin­i­cal biotech to Nas­daq as Tyra files S-1 dur­ing sum­mer lull

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The sum­mer has brought a rel­a­tive breather to the IPO mar­ket af­ter sev­er­al months of boom­ing funds, but the biotech sec­tor saw a new fil­ing last Fri­day in Tyra Bio­sciences.

Based out of Carls­bad, CA, Tyra pen­ciled in a $100 mil­lion ask ahead of the week­end, com­ing less than five months af­ter it com­plet­ed a $106 mil­lion Se­ries B. Tyra’s ul­ti­mate raise may prove greater than the ini­tial es­ti­mate as it’s raised near­ly $160 mil­lion over­all, but the biotech has yet to get any of its ex­per­i­men­tal drugs in­to hu­man test­ing, with the lead pro­gram for blad­der can­cer ex­pect­ed to see an IND fil­ing in mid-2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER